PrecisemAb Biotech drew strong attention at the BIO International Convention held in San Diego, showcasing its proprietary Universal Antibody Lock technology. Multiple biopharmaceutical companies from the United States, Japan, and South Korea expressed interest in potential collaborations with the company.
The Universal Antibody Lock technology was invented by Professor Tien-Lu Cheng at Kaohsiung Medical University and is exclusively licensed to PrecisemAb. The technology functions by installing a “lock” onto conventional antibodies, transforming them into pro-antibodies that remain inactive in healthy tissues but become selectively activated by tumor-specific proteases within the tumor microenvironment. This mechanism enhances anti-tumor precision while reducing systemic toxicity.
The platform can be broadly applied to monoclonal antibodies, ADCs (antibody–drug conjugates), AOCs (antibody–oligonucleotide conjugates), and bispecific antibodies, improving both safety and therapeutic performance. PrecisemAb has also licensed the technology to GlycoNex Inc. and has secured patent approvals across 18 countries.
Chairperson Yun-Chi Lu highlighted that the company’s lead candidate, PSM101 (a Lock-anti-EGFR antibody), has demonstrated tumor-suppressive effects in metastatic head and neck cancer models and has shown favorable safety in normal tissues. These findings further validate the platform’s translational potential and commercial value.
During the convention, numerous biotech developers, ADC/AOC platform companies, and multinational pharmaceutical firms expressed strong interest in exploring opportunities such as technology licensing, contract development, and co-development partnerships. PrecisemAb looks forward to leveraging this global stage to expand international collaborations and accelerate its path from Taiwan to the world.
source: Gene online
